No Fast Track For Lecanemab In EU Disappoints Eisai

Approval Could Come March 2024

 
• By Andrew McConaghie

Despite being hailed as a potential breakthrough for Alzheimer’s, the EMA will not fast-track lecanemab, underscoring differences with the FDA’s frequent use of accelerated pathways.

EMA
Lecanemab could be approved in the European Union by March 2024 - well over a year after the US accelerated approval. • Source: Shutterstock

More from Business

More from Scrip